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Height is a classic complex trait with common variants in a growing list of genes known to contribute to the phenotype. Using a gen-
ecentric genotyping array targeted toward cardiovascular-related loci, comprising 49,320 SNPs across approximately 2000 loci, we eval-
uated the association of common and uncommon SNPs with adult height in 114,223 individuals from 47 studies and six ethnicities.
A total of 64 loci contained a SNP associated with height at array-wide significance (p< 2.43 106), with 42 loci surpassing the conven-
tional genome-wide significance threshold (p < 5 3 108). Common variants with minor allele frequencies greater than 5% were
observed to be associated with height in 37 previously reported loci. In individuals of European ancestry, uncommon SNPs in IL11
and SMAD3, which would not be genotyped with the use of standard genome-wide genotyping arrays, were strongly associated with
height (p < 33 1011). Conditional analysis within associated regions revealed five additional variants associated with height indepen-
dent of lead SNPs within the locus, suggesting allelic heterogeneity. Although underpowered to replicate findings from individuals of
European ancestry, the direction of effect of associated variants was largely consistent in African American, South Asian, and Hispanic
populations. Overall, we show that dense coverage of genes for uncommon SNPs, coupled with large-scale meta-analysis, can success-
fully identify additional variants associated with a common complex trait.Introduction
Although complex processes such as age at puberty, peri-
natal environment, and nutritional intake affect attained
adult height, up to 90% of its variation has been attributed
to heritable factors.1,2 Height is an attractive model pheno-
type to study in an attempt to provide insights into the
genetic architecture of complex traits: it is relatively stable
over the course of adulthood, it is usually measured in rela-
tion to body mass index in large-scale population-based
and case-control studies, it is easily and accurately
measured, and it is easily harmonized across cohorts.
More than 90 years ago, Fisher proposed that many vari-
ants with small individual effects explain the heritability
of continuous, normally distributed traits, such as height.3
Recent findings from a number of genome-wide associa-
tion studies (GWAS) support this hypothesis, as common
variation in over 180 loci have now been associated with
height,4,5 but the common variants within the loci explain
less than 10% of the population variation in height.5–14
Recent work suggests that about 300,000 SNPs can explain
up to 45% of the variance in height across the popula-
tion,15 but it provides no insight into the responsible
genes. Given that all of the variants needed to explain
height have not been identified to date, the additional
genetic variants are likely to be uncommon in the popula-
tion or of very small effect, requiring extremely large
samples to be confidently identified.
Multiple genecentric genotyping arrays have been devel-
oped for replication and fine mapping of loci with known
or putative roles in specific phenotypes or disease areas.
One of the first such arrays, the ITMAT-Broad-CARe or
‘‘IBC array’’ (also referred to as the CardioChip or the
Human Cardiovascular Disease [HumanCVD] BeadChip
[Illumina]), incorporates about 50,000 SNPs to efficiently114Current address: The Children’s Hospital of Philadelphia Research Institute
115These authors contributed equally to this work.
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related to cardiovascular, inflammatory, and metabolic
phenotypes. Genetic variation within themajority of these
regions is captured at density equal to or greater than that
afforded by genome-wide genotyping products.16 The IBC
array has content derived from the International HapMap
Consortium and resequencing data from the SeattleSNPs
and National Institute of Environmental Health Sciences
(NIEHS) SNPs consortia, with a focus upon inclusion of
lower-frequency variants and variants with a higher likeli-
hood of functionality.
Using phased haplotype data from panels of densely
genotyped individuals, such as those provided by the
HapMap and the 1,000 Genomes Project, imputation is
often performed to increase the number of queried SNPs
in GWAS efforts.17 However, SNPs that are ungenotyped
or monomorphic in reference panels are not imputable,
and imputation quality drops for lower-frequency variants.
Until large-scale sequencing projects in large population-
sized cohorts become affordable, direct genotyping of
previously discovered uncommon variants is the only
method available for querying the impact of uncommon
moderate- to small-effect-sized variants.
Genes were selected for inclusion on the IBC array on
the basis of pathway analysis and previous candidate-
gene and GWAS reports of a variety of cardiovascular
disease (CVD)-related phenotypes. Although the IBC array
content is primarily biased toward CVD phenotypes,16 of
87 loci reported to be associated with adult height in
GWAS performed before 2010,4 27 are present on the array,
with 20 of the known loci covered at a density equal or
greater than that of conventional GWAS platforms. Addi-
tionally, many genes with plausible biological hypotheses
for involvement in height without prior evidence for asso-
ciation are found on the IBC array, such as genes with, 3516 Civic Center Blvd, Philadelphia, Pennsylvania 19104, USA
Genetics. All rights reserved.
Figure 1. IBC Array Height Meta-Anal-
ysis Overviewinvolvement in endocrine pathways and energy metabo-
lism.
In this study, we performedmeta-analysis of 90,446 indi-
viduals of European ancestry and 23,777 individuals from
an additional five ethnicities, including a total of 47
cohorts genotyped on the IBC array with available adult
height data. We aimed to replicate previous genetic associ-
ations with height and to find loci not previously described
to underpin this highly polygenic trait. Special attention
was paid to variants of lower minor allele frequency
(MAF) that would go undetected in studies relying on
imputation or in studies with fewer participants. Using
conditional analyses, we sought to identify multiple inde-
pendent association signals from within significant loci.
Finally, multiethnic meta-analysis was performed,
including all available participants, and the concordance
of direction of effect across ethnicities was evaluated.Material and Methods
Participating Studies
Investigators provided either individual-level genotype data with
height, age, and sex or summary-level statistics, following analysis
guidelines. Data sets included population-based cohorts, collec-
tions of cases and controls for a variety ofmetabolic and cardiovas-
cular phenotypes, and individuals participating in clinical trials.
A detailed description of the cohorts included in this study is
found in Tables S1 and S2 (available online). All participants
were required to have a measured height and to have their age
at time of measurement noted, and individuals younger than 21
years or older than 80 years were excluded from analysis. In total,
25 cohorts contributed individual-level phenotype and genotype
data for a total of 65,574 participants, forming the individual-level
phase I cohort (Figure 1, Table S1). An additional 22 cohorts
contributed summary-level results, representing an additional
48,649 subjects (Table S2), creating a total sample size of
114,223. All participating studies were required to obtainThe American Journal of Huinformed consent for DNA analysis and
to have received approval from local insti-
tutional review boards or ethics commit-
tees.
Genotyping and Quality Control
Genotyping was performed with the
genecentric IBC array, of which the design
and coverage compared to conventional
genome-wide genotyping arrays has been
described in detail elsewhere.16 In brief,
the density of tagging SNPs for over 2000
loci of interest was chosen via a priority
strategy, with a ‘‘cosmopolitan tagging’’
approach employed to capture known vari-
ation in HapMap populations. Available re-
sequencing data were used to identify
lower-frequency variants, with emphasison nonsynonymous SNPs and known or putative functional vari-
ants. Approximately 17,000 SNPs included on the IBC array have
anMAF< 0.05 in individuals of European descent. For themajority
of regions, SNPs were designed to be inclusive of the intronic,
exonic, and flanking untranslated regions (UTRs), as well as to
provide coverage of the proximal promoter regions designed for
the higher-priority loci. Of the SNPs included on the IBC array,
65% are intronic, 9.9% are in exonic, and 7.7% are nonsynony-
mous. Further details regarding SNP coverage for each locus can be
found in an online reference (see Web Resources).
From the IBC array, a total of 49,320 SNPs were clustered into
genotypes with the use of the Illumina Beadstudio software and
were subjected to quality control filters at the sample and SNP
levels, separately within each cohort. Samples with individual
call rates < 90%, gender mismatch, or duplicate discordance
were excluded. SNPs with a call rate < 95% or Hardy Weinberg
Equilibrium p< 107 were removed. Because of the low-frequency
SNPs included in the design of the human IBC array and the large
sample size of the current study, no filtering was performed on
MAF.
Statistical Analyses
Evaluation of Cryptic Relatedness
Within cohorts with family structure, only founders were included
in the analysis, with the exception of the GRAPHIC, Amish, and
PROCARDIS studies, in which family structure was maintained
and utilized in the association analysis (see Table S2). To ensure
removal of cryptic relatedness and duplicate samples, calculation
of pi_hat (bp), a measure of identity by descent, was estimated
from identity by state and sample allele frequencies via themethod
implemented inPLINK.18 For each set of duplicates ormonozygotic
twins and for those with a pairwise bp > 0.3, the sample with the
highest genotyping call rate was retained for analysis.
Evaluation of Population Stratification
For the primary analysis of both individual-level and summary-
level data, only individuals of European ancestry were included.
Self-reported ethnicity was verified by multidimensional-scaling
analysis of identity-by-state distances as implemented in PLINK,
including HapMap panels as reference standards. After pruningman Genetics 88, 6–18, January 7, 2011 9
of SNPs in linkage disequilibrium (LD) (r2 > 0.3), EIGENSOFT was
used to compute principal components for use as covariates in the
regression analyses.19,20 Additional self-reported ethnicities
(African American, South Asian, East Asian, Hispanic, and Native
American) were then examined independently via the samemeth-
odology.
Association Testing
Within all cohorts, including those with individual-level data
available and those analyzed by studies providing summary-level
results, association analysis was performed with the use of linear
regression, with height used as a continuous trait, and an additive
genetic model, including correction for age and a minimum of
the top three principal components of ancestry (described above)
for individuals of European descent and ten principal compo-
nents for all other ethnicities, as implemented in the software
package PLINK.18 Age was included as a covariate in regression
analyses for minimization of generation effects. All analyses
were performed with stratification by gender and race. In the
GRAPHIC, Amish, and PROCARDIS studies, which contained
some family relationships (n ¼ 9466 total individuals), associa-
tion was performed with the Mixed Model Analysis for Pedigrees
(MMAP) software (C.J. O’Donnell, 2008, Am. Soc. Hum. Genet.,
abstract). The genomic control inflation factor was calculated in
each cohort and used for within-study correction. For obtaining
effect-size estimates, phase I results were obtained by a fixed-
effect inverse-variance weighted meta-analysis in METAL.
In phase II (including summary-level cohorts of European
ancestry), phase III (including all individuals of European
ancestry), and phase IV (a multiethnic meta-analyses), meta-anal-
ysis was performed with the use of a fixed-effect sample-size
weighted Z-score meta-analysis in METAL.21 All reported p values
are two-sided and uncorrected for multiple testing. It is important
to note that although we label regions with either the gene near-
est to the lead SNP in the locus or a nearby known growth-related
gene for convenience, it is not possible to provide evidence of
which gene in the region is functionally responsible through
association analysis alone. Thus, it is possible that one or more
genetic variants within one or more surrounding genes could
be contributing to the association signal.
Calculating an appropriate significance threshold is challenging
in the context of an array containing hypothesis-driven, densely
covered loci, enriched for functional and nonsynonymous poly-
morphisms. Previous studies using the IBC array have used signif-
icance thresholds of p< 13 105 and p< 13 106. The Candidate
gene Association Resource (CARe) IBC array studies determined
that after accounting for LD, the effective number of independent
tests was 26,500 for African Americans and 20,500 for European
Americans, producing an ‘‘array-wide’’ statistical threshold of
p ¼ 1.9 3 106 and p ¼ 2.4 3 106, respectively, to maintain
a false-positive rate of 5%.22 We also highlight loci that are signif-
icantly associated at a more conventional genome-wide signifi-
cance threshold of p < 5.0 3 108. In genetic association studies,
power drops dramatically at low allele frequencies. For a SNP with
an effect of 7 mm per risk allele, the phase III meta-analysis of
90,446 individuals of European descent yields greater than 95%
power to detect a SNP with an MAF of 5% and 80% power for
a SNP with an MAF of 3% (a ¼ 2.4 3 106).
All loci harboring significant evidence for association were
examined for additional signals via conditional analyses in
PLINK.18 A term was added to the regression model, including
the lead SNP as a covariate, and surrounding SNPs were evaluated
for maintaining array-wide significance. Conditional analysis was10 The American Journal of Human Genetics 88, 6–18, January 7, 201performed only in European ancestry cohorts in which individual-
level data were available (n ¼ 53,394 from phase I).
After association tests were performed in the sex- and ethnicity-
stratified cohorts containing additional ethnicities, a multiethnic
meta-analysis including all available participants was performed.
Additionally, the direction of effect of the lead SNPs from the
previously identified loci was evaluated for consistency in the
three additional ethnicities with more than 1000 participants
available: African Americans (n ¼ 11,357), South Asians (n ¼
6003), and Hispanics (n ¼ 4934).Results
Phase I of investigation into height with the use of the IBC
array involved testing for association in participants of
European ancestry in which individual-level data were
available (n ¼ 53,394). In phase II of the analysis, we
sought replication in cohorts providing summary-level
data for participants of European ancestry (n ¼ 37,052),
followed by a meta-analysis of all participants of European
ancestry (n ¼ 90,446) in phase III. To ensure the validity of
our study design, we began by examining evidence in loci
previously reported to be associated with height in GWAS.
The lead SNP (rs4272) in cyclin-dependent kinase 6 (CDK6
[MIM 603368]) demonstrated strong evidence for associa-
tion in both phase I and phase II of analysis, confirming
a strong positive control for a previously described height
signal (phase I, p ¼ 2.5 3 1020; phase II, p ¼
3.2 3 1017; meta-analysis phase III, p ¼ 4.1 3 1036).
Additional previously identified height genes were also
significantly associated in phase I analysis, with the same
SNP replicating in the same direction in phase II, in the
following genes: high mobility group AT-hook 1 (HMGA1
[MIM 600701]), high mobility group AT-hook 2 (HMGA2
[MIM 600698]), T-box 2 (TBX2 [MIM 600747]), suppressor
of cytokine signaling 2 (SOCS2 [MIM 605117]), aggrecan
(ACAN [MIM 155760]) and patched Drosophila homolog
1 (PTCH1 [MIM 601309]) (phase I, p < 7 3 107; phase
II, same direction and p < 2 x106; meta-analysis,
p < 1 3 1013; Table 1).
A total of 34 genes were significantly associated with
height in phase I at array-wide significance (p < 2.4 3
106). All associated SNPs in phase I were replicated with
the same direction of effect in phase II (p < 0.05). In phase
III, 64 loci were significantly associated with height at
array-wide significance (p < 2.4 3 106) with 42 loci
surpassing the traditional genome-wide significance
threshold (p < 5.0 3 108). Of 87 GWAS-identified loci re-
ported before 2010,4 27 had SNPs that were present on the
IBC array and 20 of them surpassed array-wide signifi-
cance, 17 of them surpassing genome-wide significance
(Table 1). A SNP in strong LD with the previously reported
lead SNP in only three of the seven nonreplicated loci
(r2 > 0.3) was present (Table 2). Marginal association was
observed for all of the loci reported before 2010 that did
not reach array-wide significance (p % 0.05). Of the 64
associated loci in the current study, 33 were identified in1
a recent height meta-analysis including 183,727 individ-
uals of European ancestry by Lango Allen and colleagues.5
Some of the associated regions without previous reports
of association with height containing genes with inter-
esting biological roles include the following: myosin heavy
chain 7b (MYH7B [MIM 609928]), growth hormone
receptor (GHR [MIM 600946]), collagen type 11 alpha 1
(COL11A1 [MIM 120280]), collagen type 25 alpha 1
(COL25A1 [MIM 610025]), glucokinase regulatory protein
(GCKR [MIM 600842]), circadian locomotor output cycles
kaput (CLOCK [MIM 601851]), re1-silencing transcription
factor (REST [MIM 600571]) and Bardet-Biedl syndrome 7
(BBS7 [MIM 607590]).
A total of 22 uncommon SNPs (MAF < 5%) that were
observed to be significantly associated with human height
were found in eight loci: HMGA1, ACAN, peroxisome pro-
liferator-activated receptor delta (PPARD [MIM 600409]),
potassium channel voltage-gated KQT-like subfamily
member 1 (KCNQ1 [MIM 607542]), insulin-like growth
factor 1 receptor (IGF1R [MIM 147370]), mitogen-activated
protein kinase 14 (MAPK14 [MIM 600289]), interleukin-11
(IL11 [MIM 147681]), and mothers against decapentaple-
gic drosphila homolog 3 (SMAD3 [MIM 603109]). In two
of these genes, the uncommon allele showed the strongest
evidence for association (ACAN and KCNQ1; Table 1),
whereas in an additional two genes the uncommon SNP
was the only associated variant: IL11 (phase I, p ¼
5.4 3 1010; phase II, p ¼ 2.8 3 105; meta-analysis, p ¼
1.5 3 1013) and SMAD3 (phase I, p ¼ 1.8 3 108;
phase II, p ¼ 4.5 3 103; meta-analysis, p ¼ 1.0 3 109).
With the use of the empirical results of the current meta-
analysis, a plot of the effect size of associated variants as
a function of MAF was produced (Figure 2). Alleles in the
top right corner of the plot would be common in the
population and of large effect, making them easy to iden-
tify, but are unobserved for height. Alleles in the bottom
right corner of the plot are of small effect but can be
identified because of their high frequency in the popula-
tion. Conversely, alleles in the top left are rarer in the pop-
ulation but may be identified through their large effect
sizes.
Conditional analysis was performed for the identifica-
tion of loci harboring multiple variants independently
influencing adult height. Regression was repeated in the
phase I study cohorts, conditioned upon the lead SNP for
each of the 64 associated loci. In five loci, a second variant
obtained array-wide significance after being conditioned
upon the lead SNP (Table 3).
Male-only and female-only meta-analyses were per-
formed and tested for significant heterogeneity, which
provided no evidence of gender-specific signals of adult
height (Table S3). Because a number of the studies included
in the meta-analysis comprise CVD-related studies, we
restricted an analysis to 47,451 individuals of European
ancestry collected as healthy controls or included in
studies with a population-based ascertainment scheme.
The directions of effect for all of the 64 lead SNPs wereTheconsistent with the observations in phase III, and all
SNPs remained at least marginally significant (p < 0.05;
Table S4).
Association testing in African American (n ¼ 11,357),
South Asian (n ¼ 6003), Hispanic (n ¼ 4934), East Asian
(n ¼ 984), and Native American (n ¼ 499) populations
independently revealed no loci with array-wide signifi-
cance. In the phase IV multiethnic meta-analysis of all
available individuals (n ¼ 114,223), the significance of
seven loci fell below the array-wide significance threshold,
whereas five loci showed array-wide significance (Table S5).
Remarkable concordance of the direction of effect was
observed between ethnicities: 48 out of 64 SNPs between
Europeans and African Americans (p ¼ 3.9 3 105), 49
out of 61 SNPs between Europeans and South Asians
(p¼ 9.83 108), and 53 out of 64 SNPs between Europeans
and Hispanics (p¼ 5.03 108; Table S6). In total, 35 out of
64 SNPs were concordant across all four ethnic groups
examined (p ¼ 8.0 3 1016).Discussion
In a meta-analysis of genecentric association studies of
height, including 114,223 individuals from 47 studies
and six ethnicities, significant association was identified
for SNPs within 64 loci. Twenty previously identified
height-associated loci were replicated, providing valida-
tion of our study as positive control loci. Thirty-three of
64 associated loci reported here were identified in a recent
meta-analysis of individuals of European ancestry.5 Two
loci, IL11 and SMAD3, were uncovered via direct genotyp-
ing of uncommon nonsynonymous SNPs, which would
not have been identified with the use of standard
genome-wide genotyping arrays. Biological hypotheses
exist for many of the associated loci identified here, with
many previously unreported loci falling into known bio-
logical pathways such as energy metabolism, insulin and
growth hormone signaling, heart morphogenesis, cellular
growth and apoptosis, circadian rhythm, and collagen
formation.5 Previously unreported common variants
were identified as being associated with adult height in
or near genes known to be mutated in monogenic diseases
involving abnormal growth or height, such as COL11A1
and BBS7. Additionally, loci containing genes with no
known role in growth or height were identified, such as
ribosomal protein S6 kinase 1 (RPS6KA1 [MIM 601684])
and CDK5 regulatory subunit-associated protein 1
(CDK5RAP1 [MIM 608200]).
GWAS were conceived for testing of the hypothesis that
common genetic variants are associated with heritable
traits. Efforts to identify uncommon SNPs (MAF < 5%)
have generally been limited to the identification of vari-
ants with large effect via deep resequencing. However, it
is rational to hypothesize that lower-frequency variants
could also be associated with moderate to small effects. Re-
sequencing studies that identify uncommon variantsAmerican Journal of Human Genetics 88, 6–18, January 7, 2011 11
Table 1. Sixty-Four Loci Showing Significant Evidence for Association with Adult Height, Identified with the Use of the IBC Array
Locus
Rank Chr.
Candidate
Genea SNPa
Effect
Allele MAF
European Ancestry
Phase I
(up to 53,394)
European Ancestry
Phase II
(up to 37,052)
European Ancestry
Phase III
(up to 90,446)
p
Multiethnic
Phase IVb
(up to 114,223)
p
Reported
before 2010
In Lango
Allen et al.
(2010)5Effect p I2 (þ/) p
1 7q22 CDK6 rs4272 A 0.21 0.46 2.5 3 1020 0  3.2 3 1017 1.8 3 1036 4.1 3 1036 Yes Yes
2 6p21 HMGA1 rs1150781 C 0.09 0.73 2.2 3 1024 0 þ 3.3 3 1010 7.3 3 1032 2.0 3 1039 Yes Yes
3 12q15 HMGA2 rs867633 A 0.41 0.39 1.6 3 1020 0  4.1 3 1012 5.6 3 1031 1.7 3 1030 Yes Yes
4 20q11 MMP24 rs2425019 A 0.46 0.32 4.9 3 1014 7  6.7 3 1014 2.4 3 1026 6.4 3 1026 Yes
5 17q23 MAP3K3 rs8081612 T 0.28 0.37 6.2 3 1012 3 þ 1.6 3 107 3.2 3 1020 1.3 3 1022 Yes
6 17q24 GH1-GH2 rs7921 A 0.25 0.34 2.0 3 1013 8 þ 6.2 3 108 3.3 3 1020 3.0 3 1021 Yes
7 1p36 MFAP2 rs2284746 C 0.49 0.30 2.7 3 1012 0  1.9 3 108 1.1 3 1019 9.2 3 1019 Yes Yes
8 15q26 IGF1R rs2871865 C 0.11 0.44 7.2 3 1012 0 þ 3.5 3 108 1.3 3 1018 7.9 3 1019 Yes
9 7p22 GNA12 rs1636255 A 0.26 0.39 7.8 3 1012 19  3.6 3 108 3.0 3 1018 7.0 3 1019 Yes Yes
10 17q23 TBX2 rs9892365 A 0.33 0.25 4.4 3 109 1 þ 2.6 3 1010 1.4 3 1017 1.4 3 1017 Yes Yes
11 12q22 SOCS2 rs3782415 T 0.21 0.39 7.1 3 1015 0  2.1 3 104 1.2 3 1016 8.3 3 1016 Yes Yes
12 9q22 PTCH1 rs10512248 T 0.33 0.21 6.7 3 107 13  2.1 3 109 1.1 3 1014 5.3 3 1014 Yes Yes
13 14q11 NFATC4 rs12590407 T 0.29 0.27 2.9 3 109 0  1.9 3 106 1.5 3 1014 9.4 3 1013 Yes
14 15q26 ACAN rs16942341 T 0.03 0.73 1.8 3 109 0  1.1 3 106 2.4 3 1014 9.6 3 1016 Yes Yes
15 2q24 NPPC rs2679178 T 0.09 0.44 1.3 3 109 3  9.8 3 106 4.4 3 1014 5.8 3 1014 Yes Yes
16 6p21 PPARD rs3734254 T 0.22 0.27 3.2 3 107 26 þ 1.7 3 107 1.1 3 1013 4.7 3 1011 Yes
17 20q11 MYH7B rs2425012 A 0.43 0.25 8.0 3 109 2  5.2 3 105 3.4 3 1013 5.2 3 1012
18 19q13 IL11 rs4252548 T 0.03 0.81 5.4 3 1010 0  8.8 3 105 7.1 3 1013 2.8 3 1012
19 3q26 GHSR rs572169 T 0.30 0.25 1.8 3 108 33 þ 4.2 3 106 8.3 3 1013 9.9 3 1013 Yes
20 2p23 POMC rs1866146 A 0.34 0.23 6.5 3 108 0  7.4 3 106 2.5 3 1012 1.5 3 1011 Yes
21 5p14 NPR3 rs1173736 A 0.26 0.26 1.1 3 107 0  1.5 3 104 7.3 3 1012 1.4 3 1010 Yes Yes
22 5p13 GHR rs6180 A 0.46 0.18 1.8 3 105 0 þ 6.8 3 108 1.8 3 1011 3.1 3 1012
23 15q22 SMAD3 rs35874463 A 0.05 0.59 1.8 3 108 0  1.1 3 104 2.5 3 1011 3.4 3 1013
24 11p15 SPTY2D1 rs11024739 A 0.26 0.16 9.3 3 104 0  9.3 3 1010 3.8 3 1011 1.9 3 1010
25 11p15 KCNQ1 rs2075870 A 0.03 0.18 1.8 3 105 0  4.3 3 105 9.8 3 1011 1.8 3 108 Yes
26 1p21 COL11A1 rs4338381 A 0.37 0.18 3.6 3 105 0  9.2 3 107 1.6 3 1010 2.9 3 1010
27 9q21 PCSK5 rs11144688 A 0.12 0.32 2.2 3 107 0  1.9 3 104 3.3 3 1010 5.0 3 109 Yes
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Table 1. Continued
Locus
Rank Chr.
Candidate
Genea SNPa
Effect
Allele MAF
European Ancestry
Phase I
(up to 53,394)
European Ancestry
Phase II
(up to 37,052)
European Ancestry
Phase III
(up to 90,446)
p
Multiethnic
Phase IVb
(up to 114,223)
p
Reported
before 2010
In Lango
Allen et al.
(2010)5Effect p I2 (þ/) p
28 2p23 GCKR rs780094 T 0.41 0.17 5.8 3 105 0  1.1 3 106 6.4 3 1010 2.2 3 1011
29 1q41 TGFB2 rs900 A 0.28 0.22 5.6 3 107 0  2.7 3 104 8.0 3 1010 6.0 3 1010 Yes
30 20q11 CDK5RAP1 rs291700 T 0.31 0.22 2.4 3 107 0  7.1 3 104 9.9 3 1010 4.4 3 1010
31 2p12 EIF2AK3 rs867529 C 0.27 0.24 3.2 3 107 0 þ 5.5 3 104 1.3 3 108 1.4 3 1010 Yes
32 19p13 INSR rs8108622 A 0.23 0.24 9.9 3 107 1 þ 4.8 3 104 1.8 3 109 2.5 3 1010 Yes
33 6q25 ESR1 rs488133 T 0.33 0.21 1.8 3 106 16  2.5 3 104 2.6 3 109 1.2 3 1010 Yes
34 2q37 DIS3L2 rs3103296 T 0.37 0.23 1.1 3 107 0  3.6 3 104 4.8 3 109 9.4 3 107 Yes
35 2q35 PLCD4 rs611203 A 0.42 0.16 1.0 3 104 0 þ 9.8 3 106 5.8 3 109 7.0 3 109
36 1p36 RPS6KA1 rs3816540 A 0.23 0.19 1.1 3 104 0 þ 1.4 3 105 8.5 3 109 1.2 3 107
37 15q21 CYP19A1 rs3751591 A 0.17 0.25 6.1 3 106 0 þ 3.4 3 104 9.4 3 109 7.4 3 109 Yes Yes
38 5q31 SLC22A5 rs17622208 A 0.47 0.17 5.9 3 105 5 þ 2.1 3 105 1.1 3 108 3.2 3 1012 Yes
39 7p15 JAZF1 rs864745 T 0.50 0.21 1.8 3 105 0 þ 1.9 3 104 1.9 3 108 1.7 3 109 Yes Yes
40 17p13 POLR2A rs8071847 A 0.21 0.20 6.7 3 105 0  7.4 3 105 3.0 3 108 5.0 3 109
41 1p22 PKN2 rs12145922 A 0.43 0.15 2.6 3 104 0 þ 2.6 3 105 3.2 3 108 2.7 3 108 Yes
42 7q22 CNOT4 rs3812265 T 0.24 0.23 9.2 3 107 0 þ 9.3 3 103 3.4 3 108 9.2 3 108
43 14p11 REST rs3796529 T 0.19 0.26 5.1 3 107 32 þ 1.4 3 102 5.7 3 108 1.2 3 107
44 6p21 MICA rs2516448 A 0.49 0.21 9.3 3 104 0 þ 1.2 3 105 7.0 3 108 3.2 3 108 Yes
45 11p11 PTPRJ rs4752805 A 0.25 0.22 9.7 3 106 0  2.6 3 103 7.9 3 108 1.3 3 107
46 16p13 CASKIN1 rs258281 A 0.19 0.23 1.5 3 105 19  2.5 3 103 8.3 3 108 2.0 3 109 Yes
47 3q21 PCCB rs9844666 A 0.24 0.22 5.8 3 106 9  2.9 3 103 8.9 3 108 1.7 3 107 Yes
48 14q22 SAMD4A rs709939 T 0.46 0.15 2.5 3 104 0 þ 2.4 3 104 1.8 3 107 2.3 3 106
49 11q13 BBS1-CTSF rs4630309 A 0.24 0.23 1.8 3 106 20 þ 2.1 3 102 2.7 3 107 4.7 3 107
50 4q27 BBS7 rs7659604 T 0.41 0.20 2.2 3 106 0 þ 6.7 3 103 3.2 3 107 5.2 3 107
51 4q12 CLOCK rs4864546 A 0.37 0.21 7.3 3 107 0 þ 4.2 3 102 4.0 3 107 6.4 3 108
52 12p12 PDE3A rs7137534 T 0.32 0.18 4.0 3 105 0 þ 4.9 3 103 6.1 3 107 4.3 3 107 Yes Yes
53 12q24 MPHOSPH9 rs1051431 A 0.22 0.19 3.0 3 104 3  1.4 3 103 6.9 3 107 6.2 3 106
(Continued on next page)
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Table 1. Continued
Locus
Rank Chr.
Candidate
Genea SNPa
Effect
Allele MAF
European Ancestry
Phase I
(up to 53,394)
European Ancestry
Phase II
(up to 37,052)
European Ancestry
Phase III
(up to 90,446)
p
Multiethnic
Phase IVb
(up to 114,223)
p
Reported
before 2010
In Lango
Allen et al.
(2010)5Effect p I2 (þ/) p
54 1p22 COL24A1 rs2046159 A 0.16 0.23 3.8 3 105 25 þ 7.0 3 103 7.1 3 107 1.1 3 105
55 1q23 DUSP23 rs1129923 A 0.10 0.25 2.7 3 104 0  8.0 3 104 7.4 3 107 5.9 3 105
56 10q22 MAT1A rs7087728 A 0.18 0.22 2.2 3 104 0 þ 1.4 3 103 9.1 3 107 1.4 3 106
57 2p15 PPP3R1 rs1822469 T 0.41 0.14 7.8 3 104 9  2.2 3 104 9.3 3 107 1.4 3 105
58 7q36 ATG9B rs1800783 A 0.38 0.16 2.0 3 104 0  2.1 3 103 1.2 3 106 1.9 3 106
59 14q11 BCL2L2 rs3210043 A 0.16 0.25 9.7 3 106 0 þ 2.0 3 102 1.3 3 106 5.4 3 108
60 4p14 RFC1 rs11096991 T 0.35 0.15 3.6 3 104 0 þ 1.9 3 103 1.5 3 106 1.5 3 105
61 6p21 HLA-B rs2596494 C 0.17 0.24 1.5 3 103 12 þ 2.9 3 104 1.8 3 106 4.9 3 106 Yes Yes
62 6q21 ZBTB24 rs1476387 T 0.42 0.12 3.8 3 103 8  3.0 3 104 1.9 3 106 2.9 3 106 Yes
63 17q24 GRB2 rs959260 T 0.18 0.16 4.1 3 103 15 þ 2.8 3 104 2.1 3 106 2.1 3 106
64 19p13 ADAMTS10 rs8111085 T 0.07 0.30 3.2 3 104 0  2.6 3 103 2.2 3 106 4.0 3 106 Yes Yes
Phase I employed an inverse-variance weighted fixed-effect meta-analysis for the estimation of effect size. Phase II, phase III, and the multiethnic meta-analyses used a sample-size weighted Z-score-based fixed-effect meta-
analysis. (þ/) indicates the direction of effect in Z-based meta-analysis.
a Lead SNP in locus. Nearest gene unless there is a known growth-related gene in the locus.
b Meta-analysis results include European-descent (n ¼ 90,446), African American (n ¼ 11,357), South Asian (n ¼ 6003), Hispanic (n ¼ 4934), East Asian (n ¼ 984), and Native American (n ¼ 499).
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Table 2. Loci Previously Identified by GWAS that Failed to Replicate at Array-wide Significance in Phase III
Chr.
Candidate
Gene
Previous
Lead SNP
Lead SNP on
IBC Array
r2 between Previous
and Lead SNP on IBC Array
European Ancestry
Phase III
(up to 90,446)
p
In Lango Allen
et al. (2010)5
4q12 PDGFRA rs17690232 rs7660759 0.07 6.3 3 103
8q13 LYN rs10958476 rs13249338 0.12 2.2 3 103
9q33 PAPPA rs789550 rs7020782 0.58 9.2 3 106 Yes
12q23 IGF1 rs5742692 rs1019731 0.001 7.1 3 104
14q32 FBLN5 rs7153027 rs3783937 0.52 3.1 3 104
17q22 NOG rs4794665 rs1076352 0.06 0.03 Yes
20p12 BMP2 rs967417 rs6107869 0.06 0.05 Yestypically use a gene-based approach, totaling the number
and category of variants within specific genes, to overcome
the low power yielded by rare variants.23,24 Because the
IBC array contains many SNPs with MAFs < 5% and
a very large number of individuals have been genotyped
on the array, it provides a unique opportunity for a well-
powered test for association of lower-frequency variants
with relatively small effect sizes directly, without the
need for ‘‘mutation counting’’- or ‘‘mutation dosage’’-
based tests.
In the current meta-analysis, a total of eight genes con-
tained uncommon SNPs (MAF < 5%) significantly associ-
ated with height. Perhaps the most important discoveries
are the two loci thatwouldnothavebeen identifiedwithout
direct genotyping of the low-frequency variants. The
uncommon SNP in IL11 (rs4252548) causes an arginine-
to-histidine substitution at position 112, replacing a large
basic amino acid with a medium-sized polar amino acid.
Interleukin 11 (IL-11) is relatively undercharacterized
compared to other interleukins; however, it is known that
IL-11 signaling induces the proliferation of hematopoietic
cells and enhances bone formation and remodeling.25,26
The uncommon SNP in SMAD3 (rs35874463) causes an
isoleucine-to-valine substitution at residue 126 of SMAD3.
SMAD3 is a transcriptional modifier activated by TGF-b,27
a signaling pathway that has been implicated in height.5
In Smad3 knockout mice, a significantly smaller body size
is attained and degeneration of the spinal intervertebral
discs is observed.28 For both IL11 and SMAD3, the
uncommon alleles are associated with a reduction in at-
tained height with observed effects of 6–8 mm.We cannot
conclude from an association study whether the measured
allele is functionally responsible for the effect. Further
examination of the pleiotropic effect of the alleles can
provide clues, but in vitro and in vivo functional analyses
are required to concretely establish the effect of the geno-
typed alleles. Imputation of rs4252548 is not currently
possible with conventional GWAS data sets or the use of
surrounding SNPs on the IBC array (which contains denser
coverage than conventional genome-wide genotyping
products), and rs35874463 is not found in HapMap 3.TheDirect genotyping of these uncommon SNPs is currently
the only way to detect their association with height.
A plot of the absolute effect size versus theMAF of genetic
variants is often shown to describe the contribution of
genetics to complex traits. As meta-analyses grow in size
and genetic investigations are modified to include variants
of lower allele frequency, our ability to identify less-
common, smaller-effect SNPs, closer to the origin of the
plot, will improve. The same paradigm is likely to be true in
other complex traits, forwhich improvements in the density
of coverage for capturing more of the genetic diversity,
including lower-frequency variants, will allow additional
signals underpinning complex traits to be identified.
Pleiotropy will become more apparent as the power to
detect smaller effect sizes improves in the study of complex
traits. Many of the genes identified as being associated with
height in the current meta-analysis are also associated with
other phenotypes. Of interest, the largest overlap appears to
be with type 2 diabetes, as four genes previously reported as
being associated with fasting glucose, fasting insulin,
insulin resistance, or type 2 diabetes risk are associated
with height in the current meta-analysis: HMGA2, GCKR,
KCNQ1, and juxtaposed with another zinc finger 1 (JAZF1
[MIM 66246]).29 Genetic variation in GCKR appears
extremely pleiotropic, as the T allele of rs780094 has been
associated with numerous traits, including increased plasma
triglycerides,30 increased C-reactive protein,31 increased uric
acid,32 reduced fasting plasma glucose, and reduced insulin
resistance,33 and the same allele is now associated with
reduced adult height. Similarly, SNPs in KCNQ1 have been
associated with not only type 2 diabetes,29 but also platelet
aggregation,34 QT interval,35 and now height.
Epidemiological data have provided support of an associ-
ation between short stature and a small increase in CVD
risk.36 Because a number of the individuals included in
the current study were collected in clinical trials, case-
only, and case-control studies of CVD, there exists the
possibility that the increased prevalence of CVD among
study subjects could confound the association with height.
To remove this potential source of confounding, we per-
formed a meta-analysis including only the controls fromAmerican Journal of Human Genetics 88, 6–18, January 7, 2011 15
Figure 2. The Effect Size of Identified Height-Associated
Genetic Variants as a Function of Minor Allele Frequency
Each point is colored by the strength of association observed in
the phase III meta-analysis.case-control studies and cohorts with population-based
ascertainment strategies. Because of the decreased power
afforded by the smaller sample size of the restricted anal-
ysis, p values were reduced in comparison to those of phase
III, but all identified lead SNPs in phase III remained
marginally significant with the same direction of effect.
It appears likely that many of the loci associated with
variation in adult height in individuals of European
ancestry will have the same direction of effect in African
American, South Asian, and Hispanic populations. Associ-
ation results from the additional ethnicities did not inde-
pendently uncover array-wide or genome-wide significant
associations, which is not unexpected given the lower
power of the smaller data sets. When replication of the
lead SNPs from the European ancestry cohorts in the addi-
tional ethnicities was attempted, the direction of effect was
concordant more often than would be expected to resultTable 3. Loci with Significant Evidence of Two Independent Height A
Gene SNP Positiona MAF Phase I p
NPR3 rs1173736 32807695 0.26 1.1 3 107
rs1421811 32750027 0.39 1.1 3 104
PROCR-MMP24 rs2425019 33282831 0.46 4.9 3 101
rs8115394 33353764 0.30 9.1 3 101
NPPC rs2679178 232506105 0.09 1.3 3 109
rs3107179 232496569 0.40 4.9 3 108
PPARD rs3734254 35502988 0.22 3.2 3 107
rs7751726 35479602 0.03 1.1 3 106
ACAN rs16942341 87189909 0.03 1.8 3 109
rs938609 87199635 0.36 7.6 3 105
a National Center for Biotechnology Information (NCBI) build 36.
16 The American Journal of Human Genetics 88, 6–18, January 7, 201from chance. With the same approach used, replication
of common variants associated with lipid traits in addi-
tional ethnicities showed similar trends, suggesting that
many common alleles associated with complex traits are
likely to have similar direction of effect across ethnicities.30
The effect sizes of the associatedvariants in thismeta-anal-
ysiswere similar toprevious reports, ranging from0.15cmto
0.81 cm per allele. Unfortunately, the current study was
unable to directly compare the total extent of explained vari-
ation to previous reports, because 60 of 87 previously re-
ported height loci were not genotyped in the current study.
The current study identified five genes containing two inde-
pendent signals for associationwithheight.However, condi-
tional analysis was only possiblewithin phase I cohorts with
individual-level data available. A total of seven loci reported
tobe associatedwithheightbefore2010 failed to reacharray-
wide significance in the current study. Marginal association
was observed for all of the nonreplicated loci (p % 0.05).
Four reasons exist for a locus to fail to replicate: (1) the first
report was a false positive; (2) the current report is a false
negative; (3) differences in study design or phenotype exist;
or (4) differences in study populations exist. In all cases
except insulin-like growth factor 1 (IGF1 [MIM 147440]),
thepreviously reported lead SNPwasnot directly genotyped,
leaving inadequate coverageas a likely reason fornonreplica-
tion. Additionally, heterogeneity of study design between
cohorts contributing to themeta-analysismayhave reduced
the signal-to-noise ratio for less robust signals. Interestingly,
only three of the seven nonreplicated loci were found to be
associated in another large meta-analysis of height that was
recently reported.5
In conclusion, meta-analyses of up to 114,223 individ-
uals across six ethnic groups from 47 studies genotyped
on the genecentric IBCarray identified64height-associated
loci. Association between height and either IL11 or SMAD3
would not have been observed without the inclusion of
direct genotyping of uncommon SNPs and large sample
size. The direction of effect of common variants associatedssociation Signals
Conditional p r2 with Lead SNP D0 with Lead SNP
- - -
1.9 3 106 0.01 0.22
4 - - -
5 1.1 3 106 0.20 0.61
- - -
9.6 3 1010 0 0.03
- - -
2.5 3 107 0.01 0.35
- - -
4.6 3 109 0.05 1.00
1
withheightwas significantly concordant across individuals
of European, African American, South Asian, and Hispanic
ancestries. The increased power to identify variants of small
effect, afforded by large sample size and the dense genetic
coverage including low-frequency SNPs within loci of
interest, has resulted in the identification of association
between previously unreported genes and height.Supplemental Data
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